Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01458340 | A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | PHASE2 | COMPLETED | 295 | — | — | Dec 1, 2011 | Nov 1, 2013 | Apr 4, 2022 | 17 | United States |
The AISRS is a modified version of the ADHD Rating Scale that more accurately reflects the impact and severity of ADHD among adults. It is a clinician-administered scale that measures all 18 symptoms of adult ADHD using a Likert scale from 0 (not present) to 3 (severe). The total score ranges from 0 to 54 with a negative change from baseline indicating an improvement in severity/reduction in symptoms.
| Arm | Type | Description |
|---|---|---|
| TD-9855 Dose 1 | EXPERIMENTAL | - |
| Placebo | EXPERIMENTAL | - |
| TD-9855 Dose 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TD-9855 | DRUG | Once daily |
| Placebo | DRUG | Once daily |
Inclusion Criteria: * Subjects must meet the following ADHD diagnostic and inclusion criteria: * Subjects must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for current ADHD subtypes (ADHD combined type, ADHD predominately inattentive...